CRLHealthcare · Diagnostics & ResearchThe 16 Wall Street analysts covering Charles River Laboratories International, Inc. hold a median 12-month price target of $233 — +0.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 85 of 100 as at 1 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Charles River Laboratories International, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (86): Reported profit is backed by cash, and the company is not expanding recklessly.
Quality (61): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Size (14): Larger than most of the companies we track — more scrutinised, less often mispriced.
The rank is the raw material. Whether the rules would actually own Charles River Laboratories International, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on CRL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +0.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 20 July 2026 | CLSA | Downgrade | Hold | $219 |
| 13 July 2026 | Mizuho | Maintains | Neutral | $192 → $230 |
| 9 July 2026 | Morgan Stanley | Maintains | Overweight | $220 → $260 |
| 9 July 2026 | Morgan Stanley | Maintains | Overweight | — |
| 17 June 2026 | Morgan Stanley | Upgrade | Overweight | — |
| 29 May 2026 | CLSA | Upgrade | Outperform | — |
| 8 May 2026 | Barclays | Maintains | Overweight | — |
| 8 May 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 14 Apr 2026 | Barclays | Maintains | Overweight | — |
| 13 Apr 2026 | JP Morgan | Maintains | Neutral | — |
| 25 Feb 2026 | UBS | Maintains | Neutral | — |
| 20 Feb 2026 | Mizuho | Maintains | Neutral | — |
| 20 Feb 2026 | TD Cowen | Maintains | Buy | — |
| 19 Feb 2026 | Barclays | Maintains | Overweight | — |
| 19 Feb 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 16 Jan 2026 | Citigroup | Maintains | Buy | — |
| 13 Jan 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 18 Dec 2025 | Mizuho | Maintains | Neutral | — |
| 15 Dec 2025 | Barclays | Maintains | Overweight | — |
| 15 Dec 2025 | JP Morgan | Maintains | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 1% of US stocks
Cheaper than 44% of US stocks
Cheaper than 27% of US stocks
Cheaper than 22% of US stocks
Higher than 32% of US stocks
Higher than 38% of US stocks
Higher than 36% of US stocks
Higher than 75% of US stocks
Higher than 24% of US stocks
Higher than 38% of US stocks
Higher than 73% of US stocks
Higher than 10% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CRL appears on the weeks it earns a place.
Charles River Laboratories is scheduled to report its second-quarter results on August 5. Investors are focused on segment demand, divestitures, and whether the company can continue its earnings beat streak.
Why it matters — The Q2 report will reveal key performance trends in CRL's business segments and whether the company can maintain its pattern of exceeding earnings expectations.
Zacks Investment Research reported that Charles River Laboratories (CRL) has the right combination of key ingredients for a likely earnings beat in its upcoming Q2 report.
Why it matters — CRL watchers would care because a potential earnings beat could signal stronger-than-expected financial performance for the quarter.
The 16 Wall Street analysts covering Charles River Laboratories International, Inc. have a median 12-month price target of $233, with estimates ranging from $135 to $264. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 16 analysts covering Charles River Laboratories International, Inc., 12 rate it a Buy, 3 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Charles River Laboratories International, Inc. 85 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, Charles River Laboratories International, Inc. ranks 85 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (86 of 100).
No one can know that. What the data says: the median 12-month target from 16 analysts implies +0.7% from the last close, and Ticker Nerd's factor model ranks Charles River Laboratories International, Inc. 85 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Charles River Laboratories International, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CRL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $135 to $264 over the next 12 months.
Charles River Laboratories International, Inc. returned +38.3% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Charles River Laboratories International, Inc. is a global contract research organization that provides drug discovery, non-clinical development, and safety testing services to pharmaceutical, biotechnology, and medical device companies.
The most recent item we track (Zacks Investment Research, 30 July 2026): "Charles River Prepares to Report Q2 Earnings: What's in Store?". Charles River Laboratories is scheduled to report its second-quarter results on August 5. Investors are focused on segment demand, divestitures, and whether the company can continue its earnings beat streak.
Charles River Laboratories International, Inc. is a global contract research organization that provides drug discovery, non-clinical development, and safety testing services to pharmaceutical, biotechnology, and medical device companies. Charles River Laboratories supports clients across the early stages of research and development with research models, discovery and safety assessment services, and manufacturing solutions. Its offerings include laboratory testing, toxicology, microbiology, biologics testing, and specialized support for regulated development workflows. The company serves a broad international customer base across North America, Europe, Asia Pacific, and other regions, helping customers advance therapies through preclinical and quality-control processes. Charles River Laboratories International, Inc. is headquartered in Wilmington, Massachusetts, and remains a key service provider within the healthcare and diagnostics research market.
CEO Ms. Birgit Girshick · 18,300 employees · United States · https://www.criver.com